Home News

News

Sutro Presents Innovative Cancer Therapy Approach Using Tumor Targeted Immunostimulants

A proof of concept for a next-generation dual conjugated combination immunostimulatory antibody-drug conjugate (IADC) was release by Sutro Biopharma,...
MabPlex has started operations of two cell culture production lines of GE brand 2,000-liter single-use bioreactors. Photo Courtesy: MabPlex USA, Inc.

MabPlex Launches Two New Cell Culture Production Lines and Plans Further Expansion

MabPlex International, a fully integrated, Contract Development and Manufacturing Organization (CDMO) with sites in China (Yantai and Shanghai) and...

Five Prime Therapeutics Licenses Antibodies to Seattle Genetics

One day after Bristol-Myers Squibb and Five Prime Therapeutics announced that a randomized Phase II study testing the combination...

FDA Grants Breakthrough Therapy Designation to Enfortumab Vedotin-ejfv in First-Line Advanced Bladder Cancer

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enfortumab vedotin-ejfv (Padcev™; Astellas Pharma and...
The Eye. Image Courtesy: Pete Linforth / Pixabay

Phase Ib Study Shows Safety, Efficacy and Durability of KSI-301

Promising safety, efficacy and durability data from the ongoing Phase Ib study of Kodiak Sciences' investigational therapy KSI-301, in...

OSE Immunotherapeutics and MAbSilico to Use AI in ADC Development

OSE Immunotherapeutics,  a clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology...

LakePharma and NJ Bio to Provide Streamlined Antibody-Drug Conjugate Services

Defying the traditional division between Contract Research Organizations (CRO) and contract development and manufacturing (CDMO), LakePharma has become the...

Updated Results from Trial Shows Enfortumab Vedotin + Pembrolizumab to Shrink Tumors in the...

Updated findings from EV-103, a phase Ib/II clinical trials of enfortumab vedotin* (Padcev™; Astellas Pharma/Seattle Genetics) in combination with...
Featured Image - Laboratory. Courtesy 2019 Fotolia

Navrogen and Levena to Develop Novel ADC for the Treatment of Humoral Immuno-Suppressed Cancers

Biopharmaceutical company Navrogen, specialized in developing therapies for cancer and immune-related disorders, and Levena Biopharma, have agreed to collaborate...

Syndivia In-Licenses SATT Conectus’ DARx Technology

France-based research-driven biotechnology company Syndivia receives the exclusive license from SATT Conectus to DARx technology. The novel technology allows...